Aptorum Group Limited, a clinical stage biopharmaceutical company, announced a definitive agreement to merge with DiamiR Biosciences. The all-stock transaction will result in DiamiR becoming a wholly-owned subsidiary of Aptorum Group. Aptorum Group plans to remain listed on the Nasdaq Stock Market after the merger. The collaboration aims to leverage DiamiR's expertise in developing innovative blood-based tests for brain health and other diseases, enhancing the combined company's ability to address unmet medical needs in oncology and infectious diseases. The merger is expected to create a global life sciences company with a strong focus on non-invasive testing for brain health and other complex conditions.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。